Pharmacotherapeutic follow-up of patients using anticoagulant medication in primary care.

Not Applicable

• Conditions: Diseases of the circulatory system; Other disorders of arteries, arterioles and capillaries in diseases classified elsewhere; Coumarins.; Anticoagulants

• Registration Number: RBR-4t22trj
• Lead Sponsor: niversidade Regional do Noroeste do Estado do Rio Grande do Sul - UNIJUI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-04-30
• Study Start: 2021-09-06
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

patients using warfarin for chronic diseases, residing in the urban area of ??the city of Ijuí / RS, having consulted in a Health Unit in the city.

Exclusion Criteria

patients residing in the rural area of ??the municipality (due to the logistics for monitoring), those who stopped using warfarin before the first interview, and who did not agree to sign the informed consent form and participate in the research.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Minimizing the incidence of bleeding, assessed by direct questioning the interviewee at each visit with a decrease of at least 5% in the number of bleeding patients.;Improvement of the length of stay in the INR therapeutic range assessed by the difference between the two consecutive INR values and the target limit value, after dividing these values, the percentage of days within the therapeutic interval is obtained with a 10% increase in patients with time of permanence in the therapeutic range.

Secondary Outcome Measures

Name	Time	Method
Minimization of thrombotic events and other adverse events assessed by direct questioning to the interviewee at each visit with a 10% decrease in thrombotic events and other adverse events.;Reduction in hospital admissions assessed by direct questioning the interviewee at each visit with a 50% decrease in patients who will not be admitted during the study period.;Reduction of drug interactions identified through Micromedex® Solutions Drug Interactions including all drugs (prescribed and that each patient used in the first and last month of follow-up and individually checked each, with a minimum reduction of 10% in the number of interactions that the patient was susceptible.;Reduction in the average number of medications assessed by direct questioning the interviewee at each visit with a 10% decrease in patients who decreased the number of medications.